Cinctive Capital Management LP Takes $1.12 Million Position in Repligen Co. (NASDAQ:RGEN)

Cinctive Capital Management LP acquired a new stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 7,514 shares of the biotechnology company's stock, valued at approximately $1,118,000.

Other large investors have also added to or reduced their stakes in the company. Toronto Dominion Bank raised its stake in shares of Repligen by 1.5% in the second quarter. Toronto Dominion Bank now owns 5,207 shares of the biotechnology company's stock worth $656,000 after purchasing an additional 75 shares during the last quarter. DekaBank Deutsche Girozentrale raised its stake in shares of Repligen by 1.1% in the second quarter. DekaBank Deutsche Girozentrale now owns 7,839 shares of the biotechnology company's stock worth $982,000 after purchasing an additional 89 shares during the last quarter. Ballentine Partners LLC raised its stake in shares of Repligen by 6.2% in the third quarter. Ballentine Partners LLC now owns 1,807 shares of the biotechnology company's stock worth $269,000 after purchasing an additional 105 shares during the last quarter. Diversified Trust Co raised its stake in shares of Repligen by 3.7% in the second quarter. Diversified Trust Co now owns 2,949 shares of the biotechnology company's stock worth $372,000 after purchasing an additional 106 shares during the last quarter. Finally, CWM LLC raised its stake in shares of Repligen by 36.3% in the third quarter. CWM LLC now owns 428 shares of the biotechnology company's stock worth $64,000 after purchasing an additional 114 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on RGEN. StockNews.com upgraded Repligen from a "sell" rating to a "hold" rating in a research note on Friday, November 22nd. Wells Fargo & Company started coverage on Repligen in a report on Tuesday, August 27th. They issued an "overweight" rating and a $180.00 price objective for the company. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $205.00 price objective on shares of Repligen in a report on Thursday, September 26th. Finally, Wolfe Research started coverage on Repligen in a report on Thursday, November 14th. They issued a "peer perform" rating for the company. Four equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $190.25.

Insider Buying and Selling

In related news, Director Anthony Hunt sold 22,191 shares of the stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the transaction, the director now directly owns 139,840 shares of the company's stock, valued at $20,328,540.80. This represents a 13.70 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders own 1.20% of the company's stock.

Repligen Stock Up 0.4 %

Shares of RGEN traded up $0.59 during midday trading on Wednesday, hitting $149.09. 307,189 shares of the company's stock traded hands, compared to its average volume of 662,265. Repligen Co. has a 1 year low of $113.50 and a 1 year high of $211.13. The firm's fifty day moving average is $141.48 and its 200-day moving average is $142.15. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $8.35 billion, a price-to-earnings ratio of -402.94, a price-to-earnings-growth ratio of 4.53 and a beta of 0.96.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, beating analysts' consensus estimates of $0.34 by $0.09. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The business had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. During the same quarter last year, the business posted $0.23 EPS. The company's revenue was up 9.7% on a year-over-year basis. As a group, sell-side analysts anticipate that Repligen Co. will post 1.52 earnings per share for the current year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.